The randomized phase II OPERA study investigated the efficacy and safety of DHP107 versus IV paclitaxel in patients with HER2-negative breast cancer.<h4>Methods</h4>OPERA was conducted in the USA and Czech Republic. Here, ERBB2 is linked to breast cancer.